| Prev Close | 41.03 |
| Open | 40.59 |
| Day Low/High | 40.48 / 41.09 |
| 52 Wk Low/High | 31.43 / 48.25 |
| Volume | 1.62M |
| Avg Volume | 5.19M |
GlaxoSmithKline Plc (GSK)
40.89
0.14
0.34
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.51B |
| Market Cap | 101.99B |
| EPS | 2.40 |
| P/E Ratio | 23.74 |
| Div & Yield | 1.97 (4.76%) |
Latest News
Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope
It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.
GlaxoSmithKline Charts Prescribe Positive Outlook as It Chases Covid-19 Vaccine
The drugmaker that is partnering with Sanofi to develop a vaccine has seen its shares push higher after declining to a low in late March.
Jim Cramer: Don't Mistake the Rally for Cheering
There is no joy in stockville -- instead we have big companies with stocks rising. Here's why that is and what you need to understand about the rally amid the crisis.
Taking Stock of Recent Dividend Hikes
We've seen some high quarterly dividend increases of late, so let's pick out the crème of the crop.
GlaxoSmithKline: The Charts Are Pointing Higher
Our latest analysis and trading strategy for the the big pharma stock.
5 Best Buys for 2020 from Argus Research
Analysts from the independent research firm review their picks from last year and share their new favorites.
GlaxoSmithKline Could Trade Up to the $75 Area in the Months Ahead
Let's see what we might expect.
GlaxoSmithKline Could Rise 20% From Here
Shares of the pharma company have broken out on our Point and Figure chart.
Jim Cramer: Drug Stocks Are Too Cheap
These stocks are priced for total imperfection. That's just what you want.
GlaxoSmithKline Could Be Close to a Major Upside Move
The long-term technical view of GSK is very bullish.
China's Drugmakers Under Scrutiny After Stanford Admissions Scandal
Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?
Jim Cramer: How to Win Now, With or Without China
If we can advance without China then who the heck knows where we can go with it.
Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil
These themes are working despite the turmoil in Washington and slowing global growth.
Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative
So far 2019 is proving to be a year where things have a habit of working out right.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Get Ready to Buy the Big Upside Breakout on GlaxoSmithKline
Let's check out the charts.
Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Celgene Deal Gets the M&A Ball Rolling in the New Year
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
This 2019 Market Optimism Is Misplaced: Market Recon
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
Pfizer Shares Jump on Monday After Company Signals Higher Price Push
Pfizer pushes higher on price increases.
Tech Selloff Could Work in Favor of Pharmaceutical Stocks
Pharma could be the best parking spot for your money if the market keeps trending downward.
Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Novice Trade: EWU United Kingdom ETF
This at-the-money, long put shooter is a high risk trade, so use discretionary capital.
Novice Trade: EWU ETF
This portfolio cannot be trusted to be diversified enough.
GlaxoSmithKline Gets a Boost
Drugmaker's charts show positive signs ahead.
Gilead's Earnings Fail to Impress
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Innoviva Is Attractive Play in Biotech
Strong balance sheet and royalties are big positives for Innoviva.
Novartis to Exit its Consumer Business and 4 Other Stories You Must Know Tuesday
With Wall Street responding to one of the strongest rallies in years, here's what you need to know premarket Tuesday.
